TScan Therapeutics (NASDAQ:TCRX) Announces Quarterly Earnings Results, Beats Expectations By $0.02 EPS

TScan Therapeutics (NASDAQ:TCRX) announced its quarterly earnings data on Monday. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.02, Zacks reports. TScan Therapeutics had a negative net margin of 653.50% and a negative return on equity of 61.13%. The company had revenue of $0.54 million for the quarter, compared to the consensus estimate of $1.55 million.

TScan Therapeutics Stock Performance

Shares of NASDAQ:TCRX traded down $0.05 during trading on Wednesday, hitting $5.81. The company’s stock had a trading volume of 18,100 shares, compared to its average volume of 255,752. The company has a 50-day moving average of $6.88 and a 200-day moving average of $7.17. TScan Therapeutics has a 12 month low of $1.97 and a 12 month high of $9.69. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.23 and a quick ratio of 5.23. The firm has a market cap of $307.12 million, a price-to-earnings ratio of -4.58 and a beta of 0.83.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. BTIG Research assumed coverage on shares of TScan Therapeutics in a research report on Thursday, May 16th. They set a “buy” rating and a $12.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of TScan Therapeutics in a research note on Monday. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a research note on Tuesday. Finally, Wedbush restated an “outperform” rating and set a $10.00 target price on shares of TScan Therapeutics in a research note on Monday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $12.00.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.